MedTrace Logo

Magnesium Lactate in the Reduction of Gestational Diabetes Incidence.

NCT04037098 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-09-28

No results posted yet for this study

Summary

Gestational diabetes, occurs during the second or third trimester of pregnancy, with no prior history of diabetes; this entity can be resolved at the end of pregnancy. Magnesium is the fourth most abundant mineral in the body, It plays an essential role in the regulation of insulin metabolism, in the functions of adenosine triphosphate. In Mexico, the prevalence of hypomagnesemia is 36.3% for women. Findings suggesting that magnesium supplementation may be a beneficial indication in metabolic glucose disorders. The hypothesis of this study is: that Magnesium lactate administration is safe and reduces the incidence of gestational diabetes.

Conditions

  • Pregnancy Related

Interventions

DIETARY_SUPPLEMENT

Magnesium lactate.

2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months

DIETARY_SUPPLEMENT

Placebo

2 tablets orally every 12 hours of on inert placebo for three months

Sponsors & Collaborators

  • Coordinación de Investigación en Salud, Mexico

    lead OTHER_GOV

Principal Investigators

  • Fernando PD Guerrero · Instituto Mexicano del Seguro Social

  • Luis PD Simental · Instituto Mexicano del Seguro Social

  • Gerardo PD Martínez · Instituto Mexicano del Seguro Social

  • Cludia PD Gamboa · Instituto Mexicano del Seguro Social

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-31
Primary Completion
2022-07-31
Completion
2023-09-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04037098 on ClinicalTrials.gov